Physician profile
William O Dodd
NPI 1629576517
$1,928.44
in general payments reported to CMS, 2019-2025
23 companies · $176 in 2025
The $176 reported for 2025 was less than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $269 · 2020: $81.51 · 2021: $486 · 2022: $392 · 2023: $348 · 2024: $176 · 2025: $176.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $683 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.90 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $302.06 | 2022-2025 | Miebo, Xiidra, Infuse |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $268.73 | 2019-2021 | |
| Oyster Point Pharma, INC. | $215.10 | 2022-2025 | Tyrvaya, Ryzumvi |
| Novartis Pharmaceuticals Corporation | $162.19 | 2020-2023 | |
| Alcon Vision LLC | $161.73 | 2021-2025 | Precision7, Tryptyr |
| Johnson & Johnson Surgical Vision, INC. | $120.55 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $114.01 | 2019-2023 | Acuvue |
| Sun Pharmaceutical Industries INC. | $99.54 | 2022-2024 | |
| Abbvie INC. | $96.63 | 2022 | |
| Allergan, INC. | $71.16 | 2019-2021 | |
| Eyevance Pharmaceuticals LLC | $71.06 | 2021 | |
| Glaukos Corporation | $43.13 | 2022 | |
| Lkc Technologies, INC. | $41.90 | 2022 | |
| Dompe US, INC. | $21.07 | 2025 | Oxervate |
| Carl Zeiss Meditec Ag | $19.40 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $17.88 | 2024 | Vevye |
| Coopervision INC. | $16.30 | 2024 | Myday Contact Lens |
| Biotissue Holdings INC. | $15.54 | 2022 | |
| Maculogix, INC. | $15.13 | 2019 | |
| Thea Pharma INC. | $14.94 | 2023 | |
| Tarsus Pharmaceuticals, INC. | $14.06 | 2025 | Xdemvy |
| Carl Zeiss Meditec USA, INC. | $13.92 | 2021 | |
| Carl Zeiss Meditec, INC. | $12.41 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Dodd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.